Lana Pine

Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.

Of the 44 new recommendations, 7 were strongly recommended.

The American College of Rheumatology has updated its treatment guidelines for rheumatoid arthritis. The guideline includes 44 treatment recommendations, 7 of which are now strongly recommended.

Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."

Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.

Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss the Healthy Mind Healthy You study, which assessed 2 mindfulness programs of varying lengths, designed for people with rheumatic disease, and compared the results.

Rheumatology Network sat down with Pedro Machado, MD, PhD, to discuss his EULAR 2021 presentation entitled, “COVID-19 vaccine safety in patients with rheumatic and musculoskeletal disease.”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 4, 2021.

Roy Fleischmann, MD, discusses his presentations for EULAR 2021, which include topics about the side effects of JAK inhibitors, disease activity measures of methotrexate withdrawal among patients with rheumatoid arthritis, and the long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis.

Neil Solomons, MD, sits down to discuss his latest study, entitled “Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet,” which will be presented at EULAR 2021.

As a part of our EULAR 2021 coverage, Rheumatology Network sat down with John Botson, MD, RPh, CCD, to discuss why patients with uncontrolled gout are significantly burdened with systemic co-morbid disease, why gout is more prevalent and severe in patients who have received kidney transplants, and why such few studies have been published on the use of pegloticase in organ transplant patients.

Rheumatology Network interviewed Laura Coates, MBChB, MRCP, PhD, to discuss what her recent study adds to existing psoriatic arthritis (PsA) research, what some of the key factors are that impact a patient’s opinion of remission, and the clinical significance.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 28, 2021.

Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.

Rheumatology Networked interviewed Elena Nikiphorou, MBBS/BSc, MD (Res), to discuss her recent study that suggests self-management and resources for patients with inflammatory arthritis improve patient experience of care and outcomes by empowering and supporting them.

Rheumatology Network sat down with Daniel Hernandez, MD, and Shilpa Venkatachalam, PhD, MPH, of CreakyJoints to highlight health disparities in marginalized communities and introduce their exciting new venture, CreakyJoints Espanol.

Rheumatology Network interviewed Puja Khanna, MD, MPH, Associate Professor of Medicine from the University of Michigan, about her study that evaluated how patients with poorly controlled gout fared when they were treated with pegloticase and mycophenolate mofetil combination therapy.

Results from a joint-specific scoring system with reference atlas and ultrasonographic image acquisition in patients with juvenile idiopathic arthritis demonstrated moderate to excellent reliability for scoring of synovitis.

Rheumatology Network interviewed Nicholas Brisson, PhD, to discuss his recent study, “Association of machine learning based predictions of medial knee contact force with cartilage loss over 2.5 years in knee osteoarthritis." The study discovered that machine learning was able to develop an equation for predicting medial tibiofemoral contact force (MCF) peak, which supports the theory that mechanical loading directly contributes to disease progression.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 21, 2021.

An observational study indicated that the majority of women with rheumatoid arthritis (RA) who were of childbearing age were not currently using contraception and were not counseled on contraception practices by their physician.

Patients with gout maintained therapeutic response at 6 months when treated with a combination of methotrexate (MTX) and pegloticase, as opposed to pegloticase therapy alone.

Investigators utilized study data to further investigate the concept of patient-defined remission and identify which factors were associated with patient-defined remission or low disease activity.

A combination of adalimumab (ADA) treatment and patient support programs (PSPs) may reduce opioid use and increase medication adherence.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2021.

Patients with psoriatic arthritis and minimal disease activity who continued ixekizumab therapy fared significantly better than those who stopped using the drug, including fewer relapses related to disease activity.

Recent analysis indicated that a rheumatoid arthritis (RA) diagnosis pervaded every facet of a patient’s perception of physical activity (PA), both as motivators and as hinderances. These results may be helpful in ultimately creating a PA strategy that can support each individual and improve clinical practice.

As systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) can cause complications during pregnancy, investigators believe it is imperative that women follow the clinical practice guidelines and receive multidisciplinary counseling before trying to conceive.

Bryant England, MD, PhD, discusses his study, "Risk of COVID‐19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At‐Risk Individuals." Investigators found that patients with rheumatoid arthritis (RA) are not only at a higher risk for contracting COVID-19, they are more likely to have severe outcomes, such as hospitalization and death, when compared with the general population.

A recent study explores the correlation between work obligations and anxiety in patients with inflammatory rheumatic diseases during the second wave of the COVID-19 pandemic. Poor quality of life due to self-isolation has been reported in this patient population.